Lilly, Amylin get recommendation from EMEA for diabetes treatment exenatide

By Lisa Kerner

Charlotte, N.C., Sept. 21 - Eli Lilly and Co. and Amylin Pharmaceuticals, Inc. received a positive opinion recommending approval of exenatide for type 2 diabetes from the Committee for Medicinal Products for Human Use of the European Medicines Evaluation Agency.

In making the submission, Eli and Amylin included data collected from 35 studies including close to 4,000 patients with type 2 diabetes treated with exenatide.

The companies plan to market the adjunctive therapy for type 2 diabetes in the European Union under the brand name Byetta.

"Exenatide is an exciting treatment option for patients with type 2 diabetes who cannot control their blood sugar level effectively using the common oral medications metformin and/or sulfonylurea," Lilly's president of international operations Lorenzo Tallarigo said in a news release.

Eli Lilly is a pharmaceutical company based in Indianapolis, Ind., and Amylin is a biopharmaceutical company based in San Diego, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.